AdAlta Ltd. · ASX:1AD

AdAlta — AusBiotech Invest 2021 and BIO-Europe Digital 2021

28 slides from AdAlta's conference presentation, Oct 22, 2021

  1. Slide 1: AdAlta presentations at AusBiotech Invest and BIO-Europe

    22 October 2021 ASX Announcement ADALTA PRESENTATIONS AT AUSBIOTECH INVEST AND BIO-EUROPE For personal use only MELBOURNE Australia, 22 October 2021: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased to annou

  2. Slide 2: Notes to editor: About AdAlta

    Notes to editor About AdAlta AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, For personal use only Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of sin

  3. Slide 3: Corporate overview

    For personal use only Corporate overview October 2021

  4. Slide 4: Disclaimer

    INVESTOR PRESENTATION – OCTOBER 2021 2 Disclaimer For personal use only Investment in AdAlta is subject to This presentation may contain forward- There is no guarantee that the investment risk, including possible loss looking statements regarding the Company’s research and development of income and

  5. Slide 5: AdAlta's purpose

    INVESTOR PRESENTATION – OCTOBER 2021 3 For personal use only AdAlta’s purpose To use our unique i-body technology to create multiple novel therapeutics for debilitating diseases that have proven difficult to drug with traditional antibodies

  6. Slide 6: AdAlta today

    INVESTOR PRESENTATION – OCTOBER 2021 4 AdAlta today For personal use only • i-body platform: can create therapeutics addressing targets underserved by traditional antibodies • Fibrosis/inflammation: Lead asset AD-214 preparing for Phase II • US$3b IPF market today, multiple indication potential • Se

  7. Slide 7: What is the i-body advantage?

    INVESTOR PRESENTATION – OCTOBER 2021 5 What is the i-body advantage? All the selectivity and specificity of antibodies with greater versatility and tunability For personal use only Small size, flexible binding domain Confers unique binding capability for targets challenging traditional Accessing ant

  8. Slide 8: An immensely powerful drug discovery platform

    INVESTOR PRESENTATION – OCTOBER 2021 6 An immensely powerful drug discovery platform i-body technology can enable a wide range of therapeutic and diagnostic products For personal use only Wide range of target classes Wide range of product formats CAR-T Targeting agents Bi-specifics and multi-specifi

  9. Slide 9: Idiopathic Pulmonary Fibrosis (IPF)

    INVESTOR PRESENTATION – OCTOBER 2021 4 Idiopathic Pulmonary Fibrosis (IPF) AdAlta’s first target, already a $3b market, is a degenerative, fatal disease in dire need of improved treatment options: For personal use only i-bodies have been designed to target a novel mode of action to address this medi

  10. Slide 10: AD-214: first in class treatment for fibrosis

    INVESTOR PRESENTATION – OCTOBER 2021 8 AD-214: first in class treatment for fibrosis AD-214’s initial focus is IPF For personal use only CXCR4 First-in-class (novel mode Human of action) treatment Lung Tissue Brown stain shows increased amount of Targets a receptor called CXCR4 in fibrotic CXCR4 lun

  11. Slide 11: Phase I clinical and PET imaging inform dosing and route of administration

    INVESTOR PRESENTATION – OCTOBER 2021 9 Phase I clinical and PET imaging inform dosing and route of administration AD-214 is well tolerated in Phase I studies; PET imaging with radiolabelled AD-214 supports early transition to inhaled route of For personal use only administration Intravenous AD-214 i

  12. Slide 12: Phase II planned with inhaled formulation

    INVESTOR PRESENTATION – OCTOBER 2021 10 Phase II planned with inhaled formulation For personal use only Delivery of AD-214 by inhalation has potential to improve bioavailability, be more convenient for patients, be more cost effective, and improve partnering flexibility • AD-214 delivered direct to

  13. Slide 13: Key milestones to de-risk AD-214 development

    INVESTOR PRESENTATION – OCTOBER 2021 11 Key milestones to de-risk AD-214 development For personal use only Quarterly milestones to de-risk asset; extensive use of pre-clinical imaging; AD-214 partnering window from FY23 Key data readouts FY22 FY23 FY24 INHALATION PROGRAM MILESTONES Aerosol stability

  14. Slide 14: AD-214: multiple indication extension options

    INVESTOR PRESENTATION – OCTOBER 2021 12 AD-214: multiple indication extension options For personal use only Each additional indication could address multiple markets with U$ billion potential Data in tissue and animal models show that AD-214 may improve fibrosis across a range of fibrotic diseases a

  15. Slide 15: IPF partnering: valuable options as early as Phase I

    INVESTOR PRESENTATION – OCTOBER 2021 13 IPF partnering: valuable options as early as Phase I For personal use only IPF assets have recently yielded attractive deal terms at early stages of development – first partnering window for AD-214 in FY2023 Feb-21: License by Graviton Jul-19 license by Boehri

  16. Slide 16: Immuno-oncology (I/O) PET imaging

    INVESTOR PRESENTATION – OCTOBER 2021 14 Immuno-oncology (I/O) PET imaging For personal use only US$6.4b PET imaging market: could help identify the 20-40% of patients who will respond to revolutionary I/O drugs faster Immuno-oncology (I/O) drugs US$95 billion I/O market1 reactivate the patient’s own

  17. Slide 17: GZMB i-body asset: GE Healthcare co-development collaboration

    INVESTOR PRESENTATION – OCTOBER 2021 15 GZMB i-body asset: GE Healthcare co-development collaboration Second asset in pre-clinical development; and could generate royalty revenue sooner than a therapeutic due to shorter diagnostic For personal use only development timelines Pipeline asset at no fina

  18. Slide 18: CAR-T therapies are revolutionising cancer treatment

    INVESTOR PRESENTATION – OCTOBER 2021 16 CAR-T therapies are revolutionising cancer treatment For personal use only Reprogramming a patient’s own immune system to fight cancer is a fast growing market at the cutting edge of medicine earned by CAR-T therapy step 1 CAR engineered chemokine >US$1b produ

  19. Slide 19: i-body enabled CAR-T assets: Carina collaboration

    INVESTOR PRESENTATION – OCTOBER 2021 17 i-body enabled CAR-T assets: Carina collaboration For personal use only Third program entering discovery to generate precision engineered CAR-T products providing new hope for patients with cancer World-leading proprietary CAR-T technologies for superior acces

  20. Slide 20: Carina collaboration details

    INVESTOR PRESENTATION – OCTOBER 2021 18 Carina collaboration details For personal use only AdAlta and Carina will jointly develop up to 5 targets to create CAR-T, bi-specific CAR-T and dual CAR-T cell therapy products Up to 5 targets Significant new, shared IP – Proof of principle already achieved -

  21. Slide 21: AdAlta assets and business model

    INVESTOR PRESENTATION – OCTOBER 2021 19 AdAlta assets and business model Current strategy is based on leveraging the i-body platform to create i-body enabled assets that are wholly owned or co- For personal use only developed. The pipeline is expanding to plan Co- Precision engineered, i-body enable

  22. Slide 22: An expanding pipeline of i-body enabled products

    INVESTOR PRESENTATION – OCTOBER 2021 20 An expanding pipeline of i-body enabled products For personal use only IND PRODUCT/ PRECLINICAL, PROGRAM PARTNER DISCOVERY ENABLING PHASE I PHASE II INDICATION PRODUCT STUDIES DEV CXCR4 AD-214: Idiopathic Inhaled Pulmonary Fibrosis Intravenous AD-214: Indicati

  23. Slide 23: The potential of our strategy: Ablynx case study

    INVESTOR PRESENTATION – OCTOBER 2021 21 The potential of our strategy: Ablynx case study Multiple internal and external assets drive value, attract partners For personal use only GPCR platform exits Acquisition US$5B Feb-15 acquired by Sosei IPO Phase Ib + 7 preclinical leads US$182m US$400m +US$83m

  24. Slide 24: Milestones for remainder of FY2022

    INVESTOR PRESENTATION – OCTOBER 2021 22 Milestones for remainder of FY2022 For personal use only Milestones extended through end of FY2022 AD-214 Other Assets ü Orphan Drug Designation for AD-214 in IPF ü Results of Phase I single dose studies in healthy volunteers ü Progressing the GE Healthcare co

  25. Slide 25: Industry experienced leadership and advisors

    INVESTOR PRESENTATION – OCTOBER 2021 23 Industry experienced leadership and advisors For personal use only Team with experience from discovery through manufacturing, clinical and commercialisation Board Executive Scientific Advisory Board Dr Paul MacLeman Tim Oldham, PhD Brian Richardson Chair CEO &

  26. Slide 26: Corporate snapshot

    INVESTOR PRESENTATION – OCTOBER 2021 22 Corporate snapshot For personal use only Key financial details (18 Oct 2021) Share price performance (last 12 months) ASX code 1AD 0.25 7.0 Market capitalisation A$21.33m 6.0 0.20 Share price (12 month closing range) A$0.087 ($0.081 - 0.195) 5.0 12 month retur

  27. Slide 27: Investment proposition

    INVESTOR PRESENTATION – OCTOBER 2021 25 Investment proposition For personal use only Fibrosis/inflammation Immuno-oncology i-body platform to create value Lead asset advancing to Phase II 2 x co-development collaborations to Patented, validated i-body platform AD-214: first-in-class, multiple indica

  28. Slide 28: Contact

    For personal use only Contact: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au

AdAlta — AusBiotech Invest 2021 and BIO-Europe Digital 2021 on 6ix